Quanterix’ technology to be used in multiplex diagnostic test for
cervical disease detection
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 22, 2018--
Quanterix
Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis
with the goal of advancing the science of precision health, today
announced a collaboration agreement with OncoGenesis, a molecular
protein-based cervical screening company, to develop a quantitative,
protein biomarker diagnostic test for cervical health using Quanterix’
next-generation Simoa® Planar Technology. The two companies will jointly
complete the development of the test on Quanterix’ forthcoming SP-X™
Imaging and Analysis System and OncoGenesis will commercialize the test
in developing countries.
“We are very excited by the potential of this diagnostic test to offer
women in the developing world access to an ease-of-use, cost-effective
way of monitoring cervical disease,” said Kevin Hrusovsky, Chief
Executive Officer, President and Chairman of Quanterix. “This represents
our first step toward a diagnostic test since recently reestablishing
unrestricted rights to our Simoa technology for in vitro diagnostics,
and we are very pleased OncoGenesis selected one of our platforms to
develop this test.”
Once the CerMark™ Cervical Screening Test is developed and validated,
and after OncoGenesis obtains required regulatory approvals, women
living in areas with limited medical resources will be able to use
OncoGenesis’ iPap™ Home Collection Kit to collect cervical specimens and
safely send them to a regional laboratory. The CerMark test is being
developed to quantify specific biomarkers reflecting high-risk HPV
infection and evidence of cervical disease progression with the goal of
eliminating the subjectivity associated with typical cytology. CerMark
has the potential to provide clinicians with data to make informed
decisions on the risks and status of patient cervical disease at lower
costs and with faster turnaround compared to cytology.
“Women in many parts of the world are dying unnecessarily from cervical
disease, and we believe the CerMark test has the potential to save many
lives through early detection,” said Peter Gombrich, Executive Chairman
of OncoGenesis. “Our initial testing with Quanterix’ technology has been
very promising and we have a high degree of confidence in our ability to
develop a robust diagnostic multiplex assay for cervical disease.”
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the
goal of advancing the science of precision health. The company’s digital
health solution, Simoa, has the potential to change the way in which
healthcare is provided today by giving researchers the ability to
closely examine the continuum from health to disease. Quanterix’
technology is designed to enable much earlier disease detection, better
prognoses and enhanced treatment methods to improve the quality of life
and longevity of the population for generations to come. The technology
is currently being used for research applications in several therapeutic
areas, including oncology, neurology, cardiology, inflammation and
infectious disease. The company was established in 2007 and is located
in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
About OncoGenesis
OncoGenesis is a protein based diagnostics cervical disease company
moving its headquarters to Boston, Massachusetts, as part of its
collaborative agreement with Quanterix. The company focus along with
contracted partners is the final development and marketing of a low
cost, high-throughput, multiplex assay detecting cervical disease
progression as well as cervical cancer. Its products consist of
proprietary cervical collectors including a personal collector, which
allows women to collect their own cervical sample. The first system will
be a lab based highly sensitive protein detection means looking at
multiple patient samples via a multiplexed protein based assay. This
lab-based system will prove the value of the markers employed in the
assay, which will lead to a Point of Care system in development
utilizing the same markers. For additional information, please visit www.oncogenx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release are based on Quanterix’s expectations and assumptions as of
the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may cause Quanterix’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed
in Quanterix’s filings with the U.S. Securities and Exchange Commission,
including the "Risk Factors" sections contained therein. Except as
required by law, Quanterix assumes no obligation to update any
forward-looking statements contained herein to reflect any change in
expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005893/en/
Source: Quanterix Corporation
PAN Communications
Lindsay Poole, 617-502-4300
quanterix@pancomm.com
